Elderly patients with CML -  Chronic Myeloid Leukemia

Intermittent Imatinib (INTERIM)  treatement in  PH -CML elderly patients in stable complete cytogenetic response
June 2012,  EHA 2012

Study Reveals No Impact of Age on Outcome in Chronic Myeloid Leukemia Patients Treated With Imatinib
March 30,2011, The American Society of Hematology (ASH)

Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study
February 2011, PublMed

Treatment of the elderly population with haematological cancers: What's new from the American Society of Hematology 2010 meeting?
December 8, 2010, ecancermedicalscience

Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance
December 6, 2010, ASH 2010

Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML
December 5,2010,ASH 2010

Imatinib In Very Elderly CML Patients: What Can We Achieve?
December 4, 2010 , ASH 2010

Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis
December 2008, ASH 2008

Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment
September 2005,   Leukemia Research

An 85-Year-Old Japanese Woman with Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia with Del (5q) Successfully Treated by Intermittent Imatinib Therapy
September 23, 2004. Journal  of the American Geriatrics Society


Gleevec® Effective and Safe in Elderly with Chronic Myeloid Leukemia
2003, Cancer News